French regulators fine Swiss pharmaceutical giants Novartis and Roche for their alleged anticompetitive pay-for-delay agreements that blocked the sale of a cheaper version of a Roche-made cancer drug, say reports.
Italy announced Wednesday that it has imposed a fine of $251 million on the companies after finding evidence the competing firms colluded to prevent the sale of Roche’s cheaper cancer drug Avastin, used to tread an eye disease, to allegedly place more market favor to Novartis’s Lucentis, which costs more.
Reports say the companies partnered to market the more expensive drug.
The two companies have denied the allegations and Roche has since vowed to appeal the fines, say reports. But the sanctions follow consumer advocacy group the European Consumer Organization’s calls for an EU-wide investigation into the practice of pharma giants colluding to block the sale of a cheaper drug to promote sales of a more expensive version of the same treatment, known as a pay-for-delay scheme.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Court Order Temporarily Halts U.S. Consumer Financial Protection Bureau Layoffs
Feb 16, 2025 by
CPI
Nokia Poised to Gain EU Approval for $2.3 Billion Infinera Acquisition
Feb 16, 2025 by
CPI
Turkey Fines Frito-Lay in Antitrust Crackdown
Feb 16, 2025 by
CPI
Advances Bill to Strengthen Antitrust Enforcement Through AI
Feb 16, 2025 by
CPI
Intel Faces Potential Breakup as Broadcom and TSMC Explore Deals
Feb 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon